Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549300 | 0.86 | FERMT2 (0.68) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL1855953 | 0.86 | CCNC (0.55) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL16013594 | 0.84 | FERMT2 (0.66) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL8541628 | 0.83 | FERMT2 (0.57) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL15483262 | 0.83 | CCNC (0.52) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL14482022 | 0.82 | FERMT2 (0.53) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL7506331 | 0.82 | CCNC (0.82) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL16013593 | 0.81 | CLK4 (0.52) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL23928759 | 0.80 | KDM4E (0.54) | CCNCCDK8HTR1AADRA1DADRA1A | |
| SCHEMBL30274560 | 0.80 | KDM4E (0.54) | CCNCCDK8HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947701-B2 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-7947701-B2 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-7947701-B2 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| EP-1687312-B1 | DUAL MOLECULES CONTAINING PEROXY DERIVATIVE, THE SYNTHESIS AND THERAPEUTIC APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2010-07-14 | — | — | EP | disclosed |
| EP-1687312-B1 | DUAL MOLECULES CONTAINING PEROXY DERIVATIVE, THE SYNTHESIS AND THERAPEUTIC APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2010-07-14 | — | — | EP | disclosed |
| CN-101068821-A | Hybrid QA molecules where Q is an aminoquinoline and A is an antibiotic residue, their synthesis and use as antibacterial agents | PALUMED SA (FR) | 2007-11-07 | — | — | CN | disclosed |
| EP-1771456-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | Palumed SA (FR) | 2007-04-11 | — | — | EP | disclosed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | disclosed |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1687312-A1 | DUAL MOLECULES CONTAINING PEROXY DERIVATIVE, THE SYNTHESIS AND THERAPEUTIC APPLICATIONS THEREOF | Centre National de la Recherche Scientifique (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006024741-A2 | HYBRID QA MOLECULES WHEREIN Q IS AN AMINOQUINOLINE AND A IS AN ANTIBIOTIC RESIDUE, THEIR SYNTHESIS AND THEIR USES AS ANTIBACTERIAL AGENT | PALUMED S.A. (FR) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005049619-A1 | DUAL MOLECULES CONTAINING PEROXY DERIVATIVE, THE SYNTHESIS AND THERAPEUTIC APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | CCNC 827/4885CDK8 3151/4885HTR1A 3002/4885 |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | PRDX2, PRDX1, PRDX5 | CCNC 3067/4885CDK8 2724/4885HTR1A 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.